HEPATIC SAFETY OF OZANIMOD IN ULCERATIVE COLITIS AND RELAPSING MULTIPLE SCLEROSIS PHASE 3 TRIALS
David T. Rubin 1
Freddy Caldera 2
Jeffrey Cohen 3
Stefan Zeuzem 4
Chun-Yen Cheng 5
Shabana Ather 5
Lorna Charles 5
James K. Sheffield 5
Axel Dignass 6
1 University of Chicago Medicine Inflammatory Bowel Disease, Chicago, United States
2 University of Wisconsin School of Medicine and Public Health, Madison, United States
3 Cleveland Clinic, Cleveland, United States
4 Goethe University Hospital, Frankfurt, Germany
5 Bristol Myers Squibb, Princeton, United States
6 Agaplesion Markus Hospital, Goethe University, Frankfurt, Germany
Conference
UEG Week Vienna 2022
Citation
United European Gastroenterology Journal 2022; 10 (Supplement 8)
Login to access library content
Do you need help setting up your myUEG account?
Contact us at [email protected]